TransMedics Group (NASDAQ:TMDX) Price Target Increased to $50.00 by Analysts at Cowen

TransMedics Group (NASDAQ:TMDXGet Rating) had its price objective raised by Cowen from $45.00 to $50.00 in a research note published on Tuesday, The Fly reports.

TMDX has been the subject of a number of other reports. Cowen raised their price target on shares of TransMedics Group from $39.00 to $45.00 and gave the stock an outperform rating in a report on Tuesday, July 26th. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $39.00 to $46.00 in a report on Wednesday, May 4th. Morgan Stanley increased their price target on shares of TransMedics Group from $25.00 to $34.00 and gave the stock an equal weight rating in a research note on Wednesday, June 29th. Finally, JPMorgan Chase & Co. raised shares of TransMedics Group from a neutral rating to an overweight rating and raised their price target for the company from $26.00 to $48.00 in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, TransMedics Group currently has an average rating of Moderate Buy and a consensus price target of $46.00.

TransMedics Group Trading Up 18.4 %

Shares of NASDAQ:TMDX opened at $48.78 on Tuesday. TransMedics Group has a 52-week low of $10.00 and a 52-week high of $48.90. The company has a market cap of $1.36 billion, a P/E ratio of -28.36 and a beta of 1.63. The stock’s 50-day moving average is $32.37 and its 200-day moving average is $25.13. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.40 and a current ratio of 5.22.

TransMedics Group (NASDAQ:TMDXGet Rating) last posted its earnings results on Monday, August 1st. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative net margin of 92.76% and a negative return on equity of 69.38%. During the same quarter in the prior year, the firm posted ($0.39) earnings per share. Equities research analysts predict that TransMedics Group will post -1.58 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In related news, insider Tamer I. Khayal sold 13,504 shares of the stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $40.01, for a total transaction of $540,295.04. Following the transaction, the insider now directly owns 46,076 shares in the company, valued at $1,843,500.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Stephen Gordon sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $35.00, for a total value of $350,000.00. Following the sale, the chief financial officer now owns 5,714 shares of the company’s stock, valued at approximately $199,990. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Tamer I. Khayal sold 13,504 shares of TransMedics Group stock in a transaction on Friday, July 29th. The shares were sold at an average price of $40.01, for a total value of $540,295.04. Following the sale, the insider now directly owns 46,076 shares in the company, valued at approximately $1,843,500.76. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 151,814 shares of company stock valued at $5,633,336. Insiders own 8.70% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently modified their holdings of the stock. Envestnet Asset Management Inc. lifted its position in shares of TransMedics Group by 1.8% during the 4th quarter. Envestnet Asset Management Inc. now owns 54,236 shares of the company’s stock worth $1,039,000 after purchasing an additional 949 shares during the last quarter. Sandhill Capital Partners LLC boosted its holdings in shares of TransMedics Group by 25.4% in the 4th quarter. Sandhill Capital Partners LLC now owns 1,805,518 shares of the company’s stock worth $34,594,000 after acquiring an additional 365,473 shares in the last quarter. HarbourVest Partners LLC acquired a new position in TransMedics Group during the 4th quarter worth $2,225,000. Moody Aldrich Partners LLC lifted its holdings in TransMedics Group by 24.1% during the 4th quarter. Moody Aldrich Partners LLC now owns 166,078 shares of the company’s stock worth $3,182,000 after buying an additional 32,209 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC lifted its stake in shares of TransMedics Group by 29.4% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 266,231 shares of the company’s stock valued at $5,101,000 after purchasing an additional 60,507 shares during the period. 71.75% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Recommended Stories

The Fly logo

Analyst Recommendations for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.